• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

作者信息

Grem J L, Yee L K, Venzon D J, Takimoto C H, Allegra C J

机构信息

Division of Clinical Sciences, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889-5105, USA.

出版信息

Cancer Chemother Pharmacol. 1997;40(2):117-25. doi: 10.1007/s002800050635.

DOI:10.1007/s002800050635
PMID:9182832
Abstract

PURPOSE

The activity of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in fluorouracil catabolism, has been reported to vary according to time of day. We wished to determine whether peak and trough DPD activities occurred at uniform times in six subjects, whether individual patterns fit a discernible profile, and whether such patterns were consistent and reproducible over time.

METHODS

Mononuclear cells were isolated from peripheral blood at 3-h intervals over a 24-h period on three different dates over a 6-month period. DPD activity was determined by incubating cellular lysates with [3H]FUra and measuring [3H]dihydrofluorouracil formation over time.

RESULTS

When the data were averaged by study date for each subject, the median value for the average DPD activity (11.0 pmol/min per 10(6) cells) was significantly different from both the median peak (21.1 pmol/min per 10(6) cells, P = 0.004) and median trough activities (4.0 pmol/min per 10(6) cells, P = 0.002). Within the six subjects, the average DPD activity for the three study dates differed by a median of 2.4-fold (range 1.2- to 4.8-fold). The time at which peak and trough DPD activities occurred varied between subjects: 8 of the 17 peaks (47%) occurred between 10:00 p.m. and 6:00 a.m., 6 (35%) occurred between 8:00 a.m. and 3:00 p.m., and 3 (18%) occurred between 5:00 p.m. and 8:15 p.m. Thus, the time of day when the peak occurred was essentially randomly distributed over the 24-h period of observation (P = 0.68). Ten (59%) of the trough DPD activities occurred between 7:00 a.m. and 3:00 p.m. The median interval between the peak and trough was 6.5 h. The data were also expressed as percent of the mean for each individual's 24-h sampling period, and reordered as time from peak rather than as the actual time of day. When the combined data for all cycles was considered, the trough occurred 6-9 h after the peak, and the DPD levels subsequent to the peak did not display merely random variation (P = 0.0055).

CONCLUSIONS

DPD activity levels and the times at which peak and trough DPD activities occurred varied both between and within subjects. If fluctuations in DPD activity influence the tolerability of fixed-rate infusions of FUra, these data suggest that a single variable-rate infusion regimen may not be suitable for all patients nor for a given individual treated over several months.

摘要

相似文献

1
Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.
Cancer Chemother Pharmacol. 1997;40(2):117-25. doi: 10.1007/s002800050635.
2
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.接受持续静脉滴注5-氟尿嘧啶的癌症患者中,二氢嘧啶脱氢酶活性与血浆5-氟尿嘧啶水平之间的关系,以及酶活性和血浆药物水平昼夜变化的证据。
Cancer Res. 1990 Jan 1;50(1):197-201.
3
Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.外周血单核细胞与肝脏中二氢嘧啶脱氢酶活性之间的联系
Clin Cancer Res. 1996 Mar;2(3):507-10.
4
Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.与健康对照相比,晚期胃肠道癌患者白细胞中二氢嘧啶脱氢酶mRNA表达及血清皮质醇水平的昼夜变化。
J Cancer Res Clin Oncol. 2002 Feb;128(2):96-102. doi: 10.1007/s00432-001-0309-y. Epub 2001 Nov 30.
5
Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus.
Cancer Chemother Pharmacol. 1996;37(6):569-73. doi: 10.1007/s002800050430.
6
Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.口服乙磺酰脲与氟尿嘧啶和亚叶酸每周给药两次对二氢嘧啶脱氢酶抑制持续时间的影响。
Clin Cancer Res. 2002 May;8(5):1045-50.
7
Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
Anticancer Res. 2002 Nov-Dec;22(6B):3789-92.
8
[Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].[二氢嘧啶脱氢酶(DPD):节律与后果]
Pathol Biol (Paris). 2005 Jun;53(5):261-4. doi: 10.1016/j.patbio.2004.12.031. Epub 2005 Jan 28.
9
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.一项基于药代动力学的试验,用于预防严重的5-氟尿嘧啶毒性。
Clin Pharmacol Ther. 2006 Oct;80(4):384-95. doi: 10.1016/j.clpt.2006.06.007.
10
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.人外周血单个核细胞和肝脏中的二氢嘧啶脱氢酶活性:群体特征、新发现的缺陷患者以及5-氟尿嘧啶化疗的临床意义
Cancer Res. 1993 Nov 15;53(22):5433-8.

引用本文的文献

1
Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.氟嘧啶治疗患者的个体化治疗:关注二氢嘧啶脱氢酶的作用。
Cancer Drug Resist. 2019 Sep 19;2(3):787-802. doi: 10.20517/cdr.2018.006. eCollection 2019.
2
Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.5-氟尿嘧啶治疗药物监测与二氢嘧啶脱氢酶(DPD)表型评估相结合可能会减少5-氟尿嘧啶暴露不足的情况。
Pharmaceuticals (Basel). 2020 Nov 23;13(11):416. doi: 10.3390/ph13110416.
3
Chronopharmacokinetics of ciclosporin and tacrolimus.
环孢素和他克莫司的时辰药代动力学。
Clin Pharmacokinet. 2006;45(8):775-88. doi: 10.2165/00003088-200645080-00002.
4
How may anticancer chemotherapy with fluorouracil be individualised?氟尿嘧啶的抗癌化疗如何实现个体化?
Clin Pharmacokinet. 2006;45(6):567-92. doi: 10.2165/00003088-200645060-00002.
5
Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolism.利用与嘧啶生物合成和β-丙氨酸代谢突变的上位相互作用分析黑腹果蝇中的嘧啶分解代谢。
Genetics. 2006 Mar;172(3):1665-74. doi: 10.1534/genetics.105.052753. Epub 2005 Dec 15.
6
Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.生物体液中二氢尿嘧啶/尿嘧啶比率的昼夜节律:二氢嘧啶脱氢酶水平的潜在生物标志物。
Br J Pharmacol. 2004 Feb;141(4):616-23. doi: 10.1038/sj.bjp.0705651. Epub 2004 Jan 26.
7
Pharmacogenetics: a tool for individualizing antineoplastic therapy.药物遗传学:一种实现抗肿瘤治疗个体化的工具。
Clin Pharmacokinet. 2000 Nov;39(5):315-25. doi: 10.2165/00003088-200039050-00001.
8
Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
Invest New Drugs. 2000 Nov;18(4):365-71. doi: 10.1023/a:1006401432488.
9
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.5-氟尿嘧啶:四十余载仍在发挥作用。其临床前及临床开发综述
Invest New Drugs. 2000 Nov;18(4):299-313. doi: 10.1023/a:1006416410198.
10
Therapeutic drug monitoring of antimetabolic cytotoxic drugs.抗代谢细胞毒性药物的治疗药物监测
Br J Clin Pharmacol. 1999 Feb;47(2):131-43. doi: 10.1046/j.1365-2125.1999.00884.x.